antiIL23

Anti-IL-23 refers to a class of monoclonal antibodies that selectively bind the p19 subunit of interleukin-23, a cytokine involved in promoting Th17 cell responses and inflammation. By blocking IL-23 signaling, these agents reduce the production of downstream inflammatory mediators such as IL-17 and IL-22, diminishing tissue inflammation in autoimmune diseases. Because they target IL-23 rather than both IL-12 and IL-23, they may spare some IL-12–dependent immune functions and exhibit distinct safety profiles.

Representative anti-IL-23 antibodies include guselkumab, tildrakizumab, risankizumab, and mirikizumab. All are designed to bind IL-23 p19, leaving IL-12 signaling relatively intact. These drugs are administered by subcutaneous injection, with induction doses followed by maintenance dosing at intervals typically ranging from 8 to 12 weeks, depending on the agent.

Clinical use has been established for plaque psoriasis and, in some cases, psoriatic arthritis, with regulatory approvals in multiple regions. Additional indications such as Crohn's disease and ulcerative colitis have been explored in clinical trials, with varying regulatory outcomes. The anti-IL-23 class is part of a broader strategy to interrupt the Th17 axis in inflammatory diseases.

Safety considerations commonly include injection site reactions and upper respiratory infections. Immunomodulation raises potential risks of infections and other immune-related events; patients are monitored according to standard guidelines. As experience accumulates, comparative safety among p19 IL-23 inhibitors continues to be evaluated in real-world settings and trials.